MDxHealth SA ADR (MDXH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MDxHealth SA ADR (MDXH) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($378.00K) by net assets ($-12.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MDXH days of operational coverage to measure how many days the company can operate on defensive assets alone.
MDxHealth SA ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how MDxHealth SA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MDxHealth SA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MDxHealth SA ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.070x |
|
MIC Electronics Limited
NSE:MICEL
|
0.001x |
|
ZHEJIANG SHIBAO H YC 1
F:W4K1
|
N/A |
|
Sino-Ocean Group Holding Limited
F:3SD
|
0.462x |
|
Luxchem Corporation Bhd
KLSE:5143
|
0.003x |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
-0.049x |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
0.227x |
|
ARRAIL GROUP LTD.
F:I1D
|
N/A |
Annual Cash Flow Conversion Efficiency for MDxHealth SA ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of MDxHealth SA ADR from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of MDxHealth SA ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.09 Million | $-10.42 Million | 0.861x | +168.99% |
| 2024-12-31 | $14.84 Million | $-18.53 Million | -1.249x | +58.14% |
| 2023-12-31 | $7.21 Million | $-21.50 Million | -2.982x | +18.57% |
| 2022-12-31 | $9.31 Million | $-34.12 Million | -3.663x | -661.83% |
| 2021-12-31 | $46.90 Million | $-22.55 Million | -0.481x | +86.11% |
| 2020-12-31 | $5.85 Million | $-20.24 Million | -3.461x | -206.28% |
| 2019-12-31 | $19.72 Million | $-22.29 Million | -1.130x | -106.34% |
| 2018-12-31 | $52.12 Million | $-28.54 Million | -0.548x | -127.37% |
| 2017-12-31 | $43.55 Million | $-10.49 Million | -0.241x | +23.40% |
| 2016-12-31 | $52.74 Million | $-16.59 Million | -0.314x | +3.30% |
| 2015-12-31 | $44.26 Million | $-14.39 Million | -0.325x | +58.24% |
| 2014-12-31 | $23.78 Million | $-18.51 Million | -0.779x | -35.45% |
| 2013-12-31 | $24.54 Million | $-14.11 Million | -0.575x | +18.11% |
| 2012-12-31 | $16.02 Million | $-11.25 Million | -0.702x | -21.14% |
| 2011-12-31 | $14.67 Million | $-8.50 Million | -0.580x | +23.56% |
| 2010-12-31 | $14.26 Million | $-10.81 Million | -0.758x | -11.36% |
| 2009-12-31 | $26.94 Million | $-18.34 Million | -0.681x | -138.61% |
| 2008-12-31 | $45.44 Million | $-12.96 Million | -0.285x | +13.86% |
| 2007-12-31 | $49.75 Million | $-16.48 Million | -0.331x | -104.43% |
| 2006-12-31 | $42.21 Million | $-6.84 Million | -0.162x | +60.09% |
| 2005-12-31 | $11.95 Million | $-4.85 Million | -0.406x | +53.41% |
| 2004-12-31 | $7.04 Million | $-6.14 Million | -0.871x | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more